PMID- 32768968 OWN - NLM STAT- MEDLINE DCOM- 20210226 LR - 20210226 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 129 DP - 2020 Sep TI - Pediococcus acidilactici intake decreases the clinical severity of atopic dermatitis along with increasing mucin production and improving the gut microbiome in Nc/Nga mice. PG - 110488 LID - S0753-3322(20)30681-8 [pii] LID - 10.1016/j.biopha.2020.110488 [doi] AB - Atopic dermatitis (AD) is a chronic inflammatory skin disease that is associated with intestinal microflora. Since specific probiotics may have better efficacy for AD, we determined the efficacy of Pediococcus acidilactici SRCM102024 (PA) for treating AD in HaCaT cells and NC/Nga mice and explored the mechanism of action. AD-like pathology was induced in HaCaT cells and the dorsal skin of Nc/Nga mice by local exposure to 2,4-dinitrochlorobenzene (DNCB). In AD-lesion induced mice, PA in low-, medium- and high-dosages (5 x 10E6, 5 x 10E7 and 5 x 10E8 CFU/kg bw, respectively) and dexamethasone (3 mg/kg bw, positive-control) were orally administered for 5 weeks. The clinical AD severity, serum immunoglobulin E (IgE) and TNF-alpha, gene expressions of interleukin (IL)-4, IL-13, and TNF-alpha and gut microflora were measured. PA treatment (100-300 CFU/mL) dose-dependently increased cell survival in DNCB-induced HACAT cells. PA reduced the relative mRNA expression of PAR-2, TNF-alpha, IL-4 and IL-13 in the cells. In dorsal skin of Nc/Nga mice applied with DNCB, PA dose-dependently attenuated erythema, hemorrhage, edema, excoriation, dryness and scratching behavior and PA-H improved the clinical symptoms similar to the positive-control. PA-M and PA-H treatment significantly prevented the disturbance of the dorsal skin tissues and decreased the inflammatory cellular infiltrate of mast cells, compared to the control. PA dose-dependently reduced serum IgE and TNF-alpha concentrations and the mRNA expression of TNF-alpha, IL-4, and IL-13 in dorsal skin. In gut microflora, relative counts of Lactobacillales, Butyricicoccus and Ruminococcus were decreased in the AD-control compared to the positive-control and the PA-M and PA-H prevented their decrease. However, the positive-control increased serum AST and ALT activities, indicating liver damage as an adverse effect. In conclusion, oral treatment of PA (human equivalent 1 x 10E9-1 x 10E10) relieved the AD symptoms by dose-dependently preventing over-activation of the immune response. Oral PA intake may be a safe and effective alternative therapy for AD. CI - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Jeong, Do-Youn AU - Jeong DY AD - Department of R & D, Microbial Institute for Fermentation Industry, Sunchang, South Korea. FAU - Ryu, Myeong-Seon AU - Ryu MS AD - Department of R & D, Microbial Institute for Fermentation Industry, Sunchang, South Korea. FAU - Yang, Hee-Jong AU - Yang HJ AD - Department of R & D, Microbial Institute for Fermentation Industry, Sunchang, South Korea. FAU - Jeong, Seong-Yeop AU - Jeong SY AD - Department of R & D, Microbial Institute for Fermentation Industry, Sunchang, South Korea. FAU - Zhang, Ting AU - Zhang T AD - Department of Food and Nutrition, Obesity/Diabetes Research Center, Hoseo University, Asan, South Korea. FAU - Yang, Hye Jeong AU - Yang HJ AD - Food Functional Research Division, Korean Food Research Institutes, Wanjoo, 55365, South Korea. FAU - Kim, Min Jung AU - Kim MJ AD - Food Functional Research Division, Korean Food Research Institutes, Wanjoo, 55365, South Korea. FAU - Park, Sunmin AU - Park S AD - Department of Food and Nutrition, Obesity/Diabetes Research Center, Hoseo University, Asan, South Korea. Electronic address: smpark@hoseo.edu. LA - eng PT - Journal Article DEP - 20200706 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Cytokines) RN - 0 (Dinitrochlorobenzene) RN - 0 (Mucins) RN - 37341-29-0 (Immunoglobulin E) SB - IM MH - Animals MH - Cell Line MH - Chronic Disease MH - Cytokines/genetics/metabolism MH - Dermatitis, Atopic/metabolism/microbiology/pathology/*therapy MH - Dinitrochlorobenzene MH - Disease Models, Animal MH - *Gastrointestinal Microbiome MH - Humans MH - Immunoglobulin E/blood MH - Intestinal Mucosa/metabolism/*microbiology MH - Male MH - Mice MH - Mucins/*metabolism MH - Pediococcus acidilactici/*physiology MH - Probiotics/*administration & dosage MH - Severity of Illness Index MH - Skin/metabolism/*pathology MH - Up-Regulation OTO - NOTNLM OT - Atopic dermatitis OT - Gut microflora OT - Intestinal integrity OT - Pediococcus acidilactici OT - Scratching behavior EDAT- 2020/08/10 06:00 MHDA- 2021/02/27 06:00 CRDT- 2020/08/10 06:00 PHST- 2020/04/16 00:00 [received] PHST- 2020/06/18 00:00 [revised] PHST- 2020/06/30 00:00 [accepted] PHST- 2020/08/10 06:00 [pubmed] PHST- 2021/02/27 06:00 [medline] PHST- 2020/08/10 06:00 [entrez] AID - S0753-3322(20)30681-8 [pii] AID - 10.1016/j.biopha.2020.110488 [doi] PST - ppublish SO - Biomed Pharmacother. 2020 Sep;129:110488. doi: 10.1016/j.biopha.2020.110488. Epub 2020 Jul 6.